BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20210101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220421
DTEND;VALUE=DATE:20220701
DTSTAMP:20260516T020238
CREATED:20220425T094247Z
LAST-MODIFIED:20220519T120013Z
UID:33903-1650499200-1656633599@www.pharmajournalist.com
SUMMARY:CPhI & P-MEC China Virtual Expo Connect
DESCRIPTION:This year CPhI & P-MEC China returns as a SMART event\, combining 2 months of online event with a 3-day in-person event to help you connect for an extended period. \n \n“Virtual Expo Connect”\, to be held from 21st April – 30th June 2022\, is the digital extension of the physical CPhI & P-MEC China event that offers an online alternative for global pharma professionals. \nPowered by PharmaSources.com\, Virtual Expo Connect builds the online platform adding valued services and infinite opportunities to connect\, learn\, trade and grow. \nTo know more visit: https://www.pharmasources.com/vec2022
URL:https://www.pharmajournalist.com/event/cphi-p-mec-china-virtual-expo-connect-2/
LOCATION:Online
ORGANIZER;CN="Informa Markets":MAILTO:Yingqi.shi@imsinoexpo.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220510
DTEND;VALUE=DATE:20220513
DTSTAMP:20260516T020238
CREATED:20220105T163123Z
LAST-MODIFIED:20220106T100246Z
UID:32667-1652140800-1652399999@www.pharmajournalist.com
SUMMARY:Adenosine-Pathway Targeted Cancer Immunotherapy Summit
DESCRIPTION:Adenosine-pathway therapies have produced a plethora of promising clinical trial data that is being met with refreshed excitement\, enthusiasm\, and R&D investment for adenosine-pathway targets. \nWith reinvigorated confidence in the field\, join fellow industry and academic thought leaders at the inaugural Adenosine-Pathway Targeted Cancer Immunotherapy Summit. This is the only comprehensive forum dedicated to optimizing efficacy of adenosine-pathway targeted drugs\, overcoming challenges of resistance and immunosuppression and supercharging therapeutics to patients in need. \nFrom analyzing the latest developments in understanding adenosine signaling in the TME\, to rationalizing drug combinations that enhance patient responses\, and exploring tools that quantify adenosine to select patients\, this is the one-stop-shop event for all things adenosine-pathway. \nHarness cutting-edge insights across 3 days of exclusive content from industry heavyweights including Astrazeneca\, Takeda\, Corvus Pharmaceuticals\, iTeos Pharmaceuticals\, Domain Therapeutics and more. Leave this definitive conference equipped with novel ideas\, actionable lessons learned and new connections enabling you to progress your adenosine-pathway targeted cancer immunotherapies to the clinic. \nTo know more visit: https://ter.li/q8tgbz
URL:https://www.pharmajournalist.com/event/adenosine-pathway-targeted-cancer-immunotherapy-summit/
LOCATION:Omni Parker House\, 60 School St\, Boston\, MA\, 02108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220510
DTEND;VALUE=DATE:20220513
DTSTAMP:20260516T020238
CREATED:20220207T093750Z
LAST-MODIFIED:20220207T093750Z
UID:33162-1652140800-1652399999@www.pharmajournalist.com
SUMMARY:7th Annual 3D Tissue Models Summit 2022
DESCRIPTION:Integrate Advanced 3D Models with Scalability & Predictability to Supercharge Your Modeling Toolbox & Enhance Clinical Confidence \nFollowing the FDA’s announcement of ‘Alternative Methods Working Group’ in the summer\, 2021\, Roche’s newly opened pRED Innovation Center in Basel\, and exciting data from Recce Pharma’s anti-infective candidate using organoids\, the 7th Annual 3D Tissue Models Summit will return to Boston in May 2022 to reunite the community of drug discovery and development experts. This is the definitive meeting for drug developers to explore and integrate complex 3D models featuring 30+ real-life case studies across 2 dedicated tracks and their lessons learned. \nJoin us in May to stay ahead of the curve and through 30+ real-life case studies\, you will learn and meet trailblazers in 3D models to revolutionize your drug discovery and development protocols\, giving you greater confidence in clinical relevancy and accelerating novel treatments to patients in a safe and affordable manner! \nTo know more visit: https://ter.li/oly672
URL:https://www.pharmajournalist.com/event/7th-annual-3d-tissue-models-summit-2022/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220510
DTEND;VALUE=DATE:20220513
DTSTAMP:20260516T020238
CREATED:20220216T112754Z
LAST-MODIFIED:20220216T112754Z
UID:33261-1652140800-1652399999@www.pharmajournalist.com
SUMMARY:3rd Manufacturing Engineering & Facility Management in Pharma Summit
DESCRIPTION:Following innovative technological breakthroughs and the FDA’s Emerging Technology Program\, the pharmaceutical industry is experiencing a renaissance period with an unprecedented level of investments in new builds and next-generation technology to support novel pipeline progression. \nThe ability to commission a modern\, flexible\, compliant facility on time and a budget have never been so critical to drug developers and patients worldwide. \nThe 3rd Manufacturing Engineering & Facility Management in Pharma Summit is the industry’s first definitive discussion and networking forum designed to reunite leaders in the manufacturing and facilities fields in person after two years to share scientific breakthroughs and address challenges the industry is facing. With the pharmaceutical industry entering Pharma 4.0\, technology advances and facilities designs must adapt to a digital\, remote world to enhance tomorrow’s CGT pipeline. \nDesigned alongside the likes of Bayer\, AstraZeneca\, and Catalent\, this industry-focused forum allows you to discuss novel cutting-edge technologies\, the latest approaches of engineering modular\, flexible facilities and address the supply chain crisis. \nWith 22+ hours of content\, 3 interactive workshops\, and over 2 hours of networking with key industry leaders\, this comprehensive forum will uniquely combine leaders in the manufacturing\, engineering\, and facilities fields in one setting to share lessons learned\, case studies\, and advancements in the field. \nJoin 80+ of your peers and be part of this unique opportunity to engage in cross-industry discussions and presentations from 20+ expert speakers on sharing technology innovations that are transforming the manufacturing field\, maximizing productivity and capital efficiency through excellent engineering and facility management\, and collaborating with stakeholders to ensure on-time\, on-budget commissioning\, and validation. \nJoin us this May to maximize your facility flexibility\, asset lifespan\, productivity & compliance through excellent engineering\, robust validation & technology adoption! \nTo know more visit: https://ter.li/qe5ezy
URL:https://www.pharmajournalist.com/event/3rd-manufacturing-engineering-facility-management-in-pharma-summit/
LOCATION:Boston Park Plaza\, 50 Park Plaza\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220511
DTEND;VALUE=DATE:20220513
DTSTAMP:20260516T020238
CREATED:20220207T100435Z
LAST-MODIFIED:20220207T100435Z
UID:33172-1652227200-1652399999@www.pharmajournalist.com
SUMMARY:Injectable Drug Delivery Conference 2022
DESCRIPTION:SMi Group Introduces the 4th Annual…  \nInjectable Drug Delivery Conference 2022 \n11th May to 12th May 2022\, \nLondon\, United Kingdom \nwww.injectable-drug-delivery.com/ \nInnovations in Formulation and Device Design for Enhanced Subcutaneous Delivery \nAs Part of Europe’s leading Injectable conference series\, we will assess innovations in drug product formulation and biologics\, new technologies in device design and the use of long-release injectable compounds. \nThere is a rising demand for vaccines\, insulin\, and many modern medicines used to treat cancer and other chronic diseases. As biologics are mainly administered through the injectable route\, the significant growth in the biologics market is expected to drive the injectable drug delivery and prefilled syringe market in the coming years. The injectable drug delivery market is expected to rise at a compound annual growth rate of 12.9% reaching £915 billion by 2027. \nThis year’s event will highlight the significance of sustainability within the injectable drug delivery industry\, whilst also providing regulatory insight on the changes that have occurred. There will be an additional focus on the impact that covid has had on the success within this industry over the past year. The conference will also highlight successes within the industry and the formulation challenges of long-lasting\, highly viscous and high-volume drug delivery. \nThe benefits of attending: \n\nDiscover the new technologies and latest injectable devices being used within the industry\nDevelop your understanding of high-volume and long-acting injectable compounds\nExplore the sustainable possibilities that can be adapted within the industry for a green future\nDelve into the world of biologics and biosimilars and what these mean for the injectable drug market\nNetwork with key industry leaders and discover the leading companies within the injectables space\n\nWho should attend: \nExecutives\, Directors\, VPs\, Heads\, Principals\, Managers\, Scientists\, Researchers of: \n\nAutoinjectors\nWearables\nDevice Engineering\nHuman Factors\nCMC\nInjectables\nSterile Manufacturing\nPackaging\nRegulatory Affairs\n\nFeatured Speakers: \n\nAlexander Zuern\, Device testing manager\, Novartis International AG\nAndrew Warrington\, Project Leader & Patient Advocate\, Novartis\nBenjamin Werner\, Scientist\, Boehringer Ingelheim Pharma GmbH & Co. KG\nBjorg K Hunter\, Regulatory Manager\, Devices\, GSK\nBlake Green\, Senior Manager Regulatory Affairs\, Amgen\nCamille Dagallier\, Formulation and Drug Process Development Senior Scientist\, Sanofi\nChristopher Muenzer\, Senior Device Technology Manager\, Novartis\nJoel Richard\, Head of Technical & Pharmaceutical Operations\, MedinCell\nMark Palmer\, Scientific Leader\, Biopharm Device Engineering\, GSK\nRebecca Moses\, Director\, Core Human Factors Inc.\nRupal Nguyen\, Principal Engineer\, Allergan\nStefania Ragone\, Pharmaceutical Assessor\, Medicines & Healthcare Products Regulatory Agency (MHRA)\nTina Arien\, Principal Scientist\, Janssen Pharmaceutica\nVikas Jaitely\, Director\, Global Regulatory Affairs Transitional Medicine and Devices\, Merck\n\nPast attendees have included \nAdvanz Pharma; Amgen; AstraZeneca; BD – Becton Dickinson; Bd Medical-Pharmaceutical Systems; BD Technologies and Innovation; Becton Dickinson; Boehringer Ingelheim GmbH & Co. KG; Boehringer Ingelheim Pharma GmbH & Co. KG; BSI Group; Chugai Pharmaceutical CO. LTD.; Congenius; Core Human Factors; F Hoffmann -La Roche Inc; GlaxoSmithKline; Glenmark Pharmaceuticals Inc.; GSK; Haselmeierá; Haughton Design Ltd; Ipsen Biopharm Limited; Janssen Pharmaceutica; Janssen Pharmaceutica NV; Legacy Allergan/AbbVie; LEO Pharma A/S; MedinCell; Merck; Merck Connected Health & Devices; MHRA; Micropore Technologies Ltd; Novartis / DD&C; Novartis International AG; Novo Nordisk Pharma; Owen Mumford; Pfizer UK Limited; Raumedic AG; Roche; SABIC; Sabic SHPP; Sandoz – A Novartis Company; Sanofi; Sanofi SWI; Team Consulting; Teva Pharamceuticals; UCB; Vetter Pharma-Fertigung GmbH & Co. KG; Zealand Pharma A/S \nAdditional Contact Info: \nT: +44 (0)20 7827 6088 \nE: rjones@smi-online.co.uk \nLinkedIn: @SMi Pharma \nTwitter: @SMiPharm #SMiInjectables
URL:https://www.pharmajournalist.com/event/injectable-drug-delivery-conference-2022/
LOCATION:London\, United Kingdom
ORGANIZER;CN="SMi Events":MAILTO:rjones@smi-online.co.uk
END:VEVENT
END:VCALENDAR